Locally advanced non-small cell lung cancer: what is the optimal concurrent chemoradiation regimen?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22614963.
- Also identified by DOI 10.3949/ccjm.79.s2.07.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The optimal chemoradiation regimen for patients with locally advanced non-small cell lung cancer (NSCLC) has yet to be defined. Disease and patient heterogeneity prevent a "one size fits all" approach to treatment. Concurrent chemoradiation up front is the definitive strategy for patients with unresectable stage III NSCLC; the addition of consolidation chemotherapy following definitive treatment has produced conflicting results with respect to overall survival. Biologic therapies have yet to show value as add-on treatment to chemoradiation.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Biological Therapy
- Carcinoma, Non-Small-Cell Lung
- Chemoradiotherapy
- Lung Neoplasms